Instrumento Inactivo

Otros idiomas Antibe Therapeutics Inc Toronto S.E.

Acciones

ATE

CA0370251039

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Antibe Announces Appointment of Receiver	24/04
Antibe Therapeutics Inc. Announces Board Resignations	24/04
ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS	22/04
Antibe Therapeutics Seeks Extension of Stay of Proceedings	19/04
Antibe Provides Update on CCAA Proceedings	19/04
Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares	16/04
Antibe Therapeutics Brief: Announcing TSX Delisting Review	16/04
Antibe Announces TSX Delisting Review	16/04
ANTIBE TO FILE AN APPLICATION FOR AN INITIAL ORDER UNDER COMPANIES CREDITORS ARRANGEMENT ACT	10/04
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act	10/04
DELETED: Canadian Investment Regulatory Organization Trade Resumption - ATE	09/04
Canadian Investment Regulatory Organization Trading Halt - ATE	09/04
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act	09/04
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act	09/04
Antibe Therapeutics Inc. Announces Board Resignations	09/04
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order	01/04
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator	01/04
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01/04
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01/04
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	01/04

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Antibe Therapeutics Inc Toronto S.E.

Acciones

ATE

CA0370251039

Otros idiomas

Filtros